SNSW(SH:688117) Zheng Quan Ri Bao·2026-01-15 13:39Core Viewpoint - Shengnuo Biotech is expected to achieve significant growth in its peptide API business, driven by capacity expansion and increasing market demand, enhancing its global competitiveness in the peptide pharmaceutical market [1][2][3] Company Performance - Shengnuo Biotech forecasts a net profit attributable to shareholders of approximately 152 million to 190 million yuan for 2025, representing a year-on-year increase of about 102 million to 140 million yuan, or a growth rate of 204.42% to 280.53% [3] - The company's net profit, excluding non-recurring gains and losses, is expected to be around 149 million to 186 million yuan, reflecting a year-on-year increase of approximately 103 million to 140 million yuan, or a growth rate of 226.07% to 307.58% [3] Market Dynamics - Shengnuo Biotech's API products are sold in regions including Europe, the United States, and South Korea, establishing partnerships with well-known pharmaceutical companies such as Fresenius Kabi and others [2] - The global demand for GLP-1 (glucagon-like peptide-1) drugs is high, significantly driving the company's performance [2] - The global peptide drug market is projected to reach 210.8 billion USD by 2030, indicating a strong growth trajectory for the industry [2] Operational Strategy - Shengnuo Biotech is focused on expanding its production capacity while exploring domestic and international markets, which is expected to lead to a steady increase in overall performance [1] - The company has successfully launched several key projects, including a peptide API production line with an annual capacity of 395 kilograms and a formulation industrialization project [1] - The company has developed a differentiated capability through its GMP production capacity system, which helps mitigate risks associated with reliance on single customers [4]